By Deena Beasley Oct 7 (Reuters) – Novartis’ experimental del-desiran for a rare type of muscular dystrophy was expected to be a winner, with the Swiss company's CEO predicting annual peak sales of $5
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Oct 7 (Reuters) - Applied Digital's first-quarter revenue more than quadrupled, while its net loss…
* CENTINEL SPINE HOLDCO - ANNOUNCES INITIAL PUBLIC OFFERING OF CLASS A COMMON STOCK -…
Oct 7 (Reuters) - Lululemon Athletica on Wednesday named industry veteran and former Nike vice…
The bad news for the Tampa Bay Lightning is the power play continues to struggle…
Oct 7 (Reuters) - Chipmaker Wolfspeed said on Wednesday it has received a conditional loan…
Oct 7 (Reuters) - Lululemon Athletica on Wednesday named industry veteran and former Nike vice…